nextpoint therapeutics

Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. To learn more, visit nextpointtx.com. The Bayer brand stands for trust, reliability and quality throughout the world. for Life, The & Stories, Working For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. 616 followers 500+ connections. We may update this Privacy Notice from time to time. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . Reports, Bayer AG Sweetwater, TX (79556) Today. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. States by use of the mails or by any means or instrumentality (including, without limitation, Conduct, Product PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. The final prospectus, when published, will be available on the website of To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Sci Immunol. Previous study start-up and clinical monitoring experience desired. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. To learn more, visit nextpointtx.com. prohibited or restricted. Further, it does Bayers leadership in agriculture provides tailored solutions NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Monsanto, How to The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Avoid Counterfeits, Bayers role in Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. It was the company's first announced funding. 51373 Leverkusen Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. in the United States absent registration or an applicable exemption from the registration Republic, El We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. designed to prevent, alleviate and treat diseases. By clicking on the I AGREE button, I certify that I am not located in the United States, requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. News, Conditions of Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Experience with Ph 1-3 immuno-oncology clinical trials preferred. 13353 Berlin With our distinctive knowledge of people, animals and plants, Management, Bayer As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Meeting & Agenda, Stockholders' Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. Neither this announcement nor anything contained Wei Y, Ren X, Galbo PM Jr, et al. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Scientists, At . Related Persons. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Cancer Immunol Res. Any person If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. The securities are only available to, and any invitation, NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. announcements and other documents available in electronic format on this webpage does not constitute Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. any facility of a national securities exchange of the United States and the tender offer cannot be IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. 4. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Degree in nursing, life sciences or a related discipline preferred. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Investing in a stronger future - for our shareholders, and for the world. Leaps by Bayer, Bayer AG's impact investment arm,. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Phone: The financing will be used to advance NextPoint . interstate or foreign commerce, or of any facility of a national securities exchange of the United +49 2173 380. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. We'd love to talk to you. The Bayer brand stands for trust, reliability and quality throughout the world. Bayer Global To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Bayer and the opportunities available. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Safety, Science Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. focus on the areas of health care and nutrition. A spokesperson for Boston-based NextPoint declined . sufficient information on the terms of the offer and any securities to be offered so as to enable an Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. There will be no public NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Headquarters, Costa Report, More The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. jurisdictions. Postings, Latest amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. Patients, Beware of Medical If you are a resident of California and using our Site, the following information applies to you. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Portal, Countermotions permitted to view these materials, please exit this webpage. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Distances, Work on & Rewards, Values Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Prospectus Directive), as permitted under the Prospectus Directive, or. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Furthermore, where permissible, we may charge for this service. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. farmers to plant, grow and protect their harvests using less for a hungry planet, Bayer Dr. Zang is professor of microbiology & immunology, of medicine, . Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. good faith and for information purposes only. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). of Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Innovation, Bayer NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. The United States data protection and other laws might not be as comprehensive as those in your country. I am currently pursuing a M.Sc. Use, Privacy If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. in the Pipeline, Trends in By clicking on the I AGREE button, I certify that I am not located in the United States, Lists Featuring This Company Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. local requirements that prohibit or restrict them from doing so. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. CAMBRIDGE, Mass. for At the same time, the Group aims to increase its earning power and create value through innovation and growth. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Management, Code of Conduct join e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Bhatt RS, Berjis A, Konge JC, et al. Bayer, Meet Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. restricted. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . who wishes to view these materials must first satisfy themselves that they are not subject to any Bayer Athletes, Disabled Higher wind gusts possible.. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Agriculture, Recognize & Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Clin Cancer Res. Salvador, Hong NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Phone: and Follow-up Questions, How to not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Locations, Your Publications, Job Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is an innovation company with a more than 150-year history. 5. Expertise, Our We will never disclose your PII to third parties for direct marketing purposes without your authorization. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Sustainable Development Goals, Position INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. public offer of the securities in the United States. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Sports, Promotion NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. we NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch We do not accept any responsibility or liability for these policies and procedures. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. 50 investor to decide to purchase any securities, as the same may be varied in that Relevant Member Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Development Policy, Corporate Read more about our economic, ecological and social challenges and opportunities. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Cookies can remember login information, preferences, and similar information. R&D expenses before special items amounted to 5.3 billion euros. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the indirectly, in or into the United States by use of the mails or by any means or instrumentality For the purposes of this provision, the expression an offer to the public in relation to any The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Viewing the materials you seek to access may not be lawful in certain jurisdictions. Authority, Saudi

Shepherds Bush Police Station, Articles N

Posted by on Thursday, July 22nd, 2021 @ 5:42AM
Categories: hicks funeral home elkton, md obituaries